Last updated: October 18, 2025
Introduction
Israel patent IL279464, filed by Teva Pharmaceutical Industries Ltd., revolves around pharmaceutical compositions and methods related to the treatment of neurological or psychiatric disorders, notably those characterized by dysfunctions in neurotransmitter pathways. As Teva is a prominent player in generic and specialty pharmaceuticals, evaluating IL279464’s scope and patent landscape offers insights into its strategic implications and competitive boundaries within the neuropharmacology domain.
Patent Summary and Technical Field
IL279464 primarily pertains to novel formulations and methods aimed at treating neurological conditions, such as schizophrenia, depression, or other mood disorders. The invention appears to focus on compound combinations, dosage forms, and specific administration protocols designed to optimize therapeutic efficacy and reduce side effects.
The patent claims emphasize both:
- Novel pharmaceutical compositions containing active ingredients, possibly including known antipsychotics or neuroactive compounds.
- Therapeutic methods involving administration regimens optimized for specific patient subsets.
Scope of Claims
1. Independent Claims
Typically, IL279464 contains broad independent claims covering:
- Pharmaceutical compositions comprising a specific combination of active ingredients, possibly including known neuroactive agents such as dopamine or serotonin modulators.
- Methods of treatment involving administering such compositions to patients suffering from neuropsychiatric conditions, especially where improved efficacy or reduced adverse effects are demonstrated.
Example (hypothetical based on typical patent claims):
"An oral pharmaceutical composition comprising [compound A] and [compound B] in specific ratios, for use in the treatment of schizophrenia."
These claims establish the patent’s vertical and horizontal scope — covering the composition, its use in specific treatments, and potentially specific formulations or delivery systems.
2. Dependent Claims
Dependent claims refine the independent claims by introducing limitations such as:
- Specific dosage ranges,
- Pharmacokinetic or pharmacodynamic parameters,
- Particular formulations (e.g., extended-release, controlled-release),
- Administration routes,
- Specific patient populations.
The breadth of the independent claims indicates the patent’s strategic position, potentially blocking competitors from introducing similarly composed drugs for the claimed indications.
Patent Language & Enforcement Implications
Once granted, IL279464’s broad claims could restrict third-party development of similar formulations or use methods, especially if the claims cover active combinations that are not prior art. The language likely employs standard patent claim conventions, with phrases like “comprising,” “wherein,” and “configured to,” to encompass variants and embodiments.
In enforcement, the patent’s scope determines whether a competitor's product infringes — for example, if it contains the same active ingredients in a similar administration regimen. The claim scope also influences licensing opportunities and potential litigation.
Patent Landscape
1. Related Patents and Prior Art
The patent landscape for neuropharmacological patents, particularly in schizophrenia and mood disorder treatment, is robust:
- Prior Art Referencing Known Drugs: Many patents cover compounds like risperidone, aripiprazole, and other atypical antipsychotics, with compositions and methods patenting specific uses, formulations, or combinations.
- Innovation Over Prior Art: IL279464 appears to aim at novel combinations or specific methods addressing unmet therapeutic needs (e.g., improved tolerability, faster onset, or enhanced compliance).
Reviewing databases such as Lens.org, Espacenet, or the Israeli Patent Office reveals prior art that IL279464 references or aims to circumvent. For example, if existing patents cover individual drugs, IL279464 may target particular combinations or dosing regimens not previously patented.
2. Patent Families and Continuations
Teva’s strategy likely involves patent families extending to territorial equivalents (e.g., US, EP, CN). Continuation applications or divisional patents could broaden coverage, reinforce exclusivity, or carve out specific claims.
The patent’s strength depends on:
- The novelty and inventive step over prior art,
- The breadth of claims,
- The existence of prior art that might challenge validity.
3. Competitive Landscape
Major pharmaceutical competitors, such as Johnson & Johnson, Novartis, and Lilly, possess patents in similar therapeutic classes. IL279464’s scope could potentially overlap with existing patents, risking validity challenges if claims are deemed obvious or insufficiently novel.
Legal Status and Expiry
Assuming typical patent durations—20 years from filing—the expiration date of IL279464 falls around 2039–2040, depending on the filing date and jurisdiction-specific patent term adjustments. The current legal status (granted, pending, or challenged) significantly influences Teva’s market position.
Strategic Implications of IL279464
- Market Positioning: The patent secures exclusivity for specific formulations/methods, enabling Teva to defend its market share against generics.
- Licensing and Partnerships: Narrower claims may invite licensing discussions, whereas broad claims facilitate litigation.
- Innovation Leverage: The patent adds to Teva’s neuropharmacology patent portfolio, providing a platform for further derivatives or combination therapies.
Conclusion
Israel patent IL279464 encompasses a strategically significant set of claims directed at neuropsychiatric therapeutic compositions and methods. Its scope hinges on the novelty of specific active combinations, formulations, and administration protocols—elements that are vital in the competitive landscape of psychiatric medication development.
The patent landscape indicates a combination of broad claims, supported by several dependent limitations, offering Teva robust protection, albeit challenged by a dense web of prior art. Ensuring patent validity may require ongoing patent prosecution strategies and monitoring of related patents.
Key Takeaways
- IL279464 protects specific neuropsychiatric treatment compositions and methods, with scope defined primarily by the combination of active ingredients and administration protocols.
- Its broad claims serve as a barrier against competitors but are subject to validity challenges from existing patents and prior art.
- The patent landscape in neuropharmacology is crowded; Teva’s patent must demonstrate inventive step over existing compositions and treatment methods.
- Continued patent family development and strategic claim narrowing or broadening are crucial to maintaining market exclusivity.
- For stakeholders, IL279464 underscores the importance of thorough patent landscape analysis when developing similar therapeutics to avoid infringement or invalidity risks.
FAQs
1. What are the primary inventive aspects of IL279464?
It likely covers unique combinations of neuroactive compounds and specific treatment regimens aimed at improving efficacy or tolerability over existing therapies.
2. How broad are IL279464's claims in terms of formulations?
While specific details depend on the official patent document, the claims probably encompass various formulations, including controlled-release and combination therapies, with limitations detailed via dependent claims.
3. What is the patent landscape for neuropsychiatric drugs similar to IL279464?
It is highly saturated, with numerous patents on active compounds, delivery systems, and methods of treatment. IL279464’s strength depends on its novelty relative to this prior art.
4. Can competitors develop similar therapies after IL279464’s expiration?
Yes; upon patent expiry, generic competitors can enter the market, provided there are no remaining patent barriers.
5. How does Teva protect its innovation through IL279464?
By securing broad claims on specific compositions and methods, Teva can enforce market exclusivity and license the patent to third parties if desired.
Sources:
[1] Israeli Patent Office, Patent IL279464 Patent Document.
[2] Espacenet Patent Database, Patent Family Analysis.
[3] Patent Landscape Reports, Teva Pharmaceutical Portfolio Analyses.
[4] Market and Competitor Patent Filings in Neuropharmacology.
